Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MLYCD | O95822 | 2/20 | 0.43 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113434 | 0.86 | CES2 (0.67) | CES2ACHEMLYCDCES1NOTUM | |
| SCHEMBL14169808 | 0.85 | CES2 (0.50) | CES2CES1TRPV1NOTUMGAA | |
| SCHEMBL31133402 | 0.82 | CES2 (0.52) | CES2TRPV1NOTUMGAARXRA | |
| SCHEMBL2771570 | 0.82 | CES2 (0.52) | CES2TRPV1NOTUMGAARXRA | |
| SCHEMBL5227982 | 0.81 | CES2 (0.50) | CES2CES1TRPV1NOTUMGAA | |
| SCHEMBL26473968 | 0.81 | CES2 (0.50) | CES2TRPV1NOTUMGAARXRA | |
| SCHEMBL1827001 | 0.80 | CES2 (0.54) | CES2ACHEMLYCDCES1NOTUM | |
| SCHEMBL18627180 | 0.78 | CES2 (0.57) | CES2TRPV1NOTUMGAARXRA | |
| Water SCHEMBL1836290 | 0.78 | CES2 (0.52) | CES2ACHEMLYCDCES1NOTUM | |
| SCHEMBL980627 | 0.77 | CES2 (0.50) | CES2ACHEMLYCDCES1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318757-B2 | Substituted isoxazoline compound and pest control agent | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8242283-B2 | Isoxazoline compound and pesticide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-08-14 | — | — | US | disclosed |
| US-20110172414-A1 | ISOXAZOLINE COMPOUND AND PESTICIDE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7947715-B2 | Isoxazoline compound and pesticide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20110009438-A1 | SUBSTITUTED ISOXAZOLINE COMPOUND AND PEST CONTROL AGENT | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-01-13 | — | — | US | disclosed |
| EP-2199287-A1 | SUBSTITUTED ISOXAZOLINE COMPOUND AND PEST CONTROL AGENT | Nissan Chemical Industries, Ltd. (JP) | 2010-06-23 | — | — | EP | disclosed |
| US-20090156643-A1 | Substituted isoxazoline compound and pesticide | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172414-A1 | ISOXAZOLINE COMPOUND AND PESTICIDE | HCRTR1, HAX1, CHRM1 | CES2 959/4885ACHE 113/4885MLYCD 3392/4885 |
| US-20090156643-A1 | Substituted isoxazoline compound and pesticide | HCRTR1, CBR1, CHRM1 | CES2 867/4885ACHE 79/4885MLYCD 3124/4885 |
| US-20110009438-A1 | SUBSTITUTED ISOXAZOLINE COMPOUND AND PEST CONTROL AGENT | CCR10, H1-10, CCL11 | CES2 1100/4885ACHE 347/4885MLYCD 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.